Cardiovascular risk factors in polycystic ovary syndrome

References

• Austin MA, Breslaw JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. 1998. Low-density lipoprotein subclass patterns and risk of myocardial infarction. Journal of the American Medical Association 260:1917–1921.
   Google Scholar
• Campos SP, Baumann H. 1992. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Molecular and Cellular Biology 12:1789–1797.
   PubMed Web of Science ®Google Scholar
• Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. 1992. Risk factors for coronary artery disease in lean and obese PCOS. Clinical Endocrinology 37:119–125.
   PubMed Web of Science ®Google Scholar
• Cussons AJ, Stuckey BG, Watts GF. 2006. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 185:227–239.
   PubMed Web of Science ®Google Scholar
• Dalton M, Cameron AJ, Zimmet PZ, Shaw JE, Jolley D, Dunstan DW, et al 2003. Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. Journal of Internal Medicine 254:555–563.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. 2007. Pathophysiology and types of dyslipidemia in PCOS. Trends in Endocrinology and Metabolism 18:280–285.
   PubMed Web of Science ®Google Scholar
• Ducluzeau PH, Cousin P, Malvoisin E, Bornet H, Vidal H, Laville M, et al 2003. Glucose-to-insulin ratio rather than sex hormone binding globulin and adiponectin levels best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 88:3626–3631.
   PubMed Web of Science ®Google Scholar
• Dunaif A. 1997. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocrine Reviews 18:774–800.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. 1999. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22:141–146.
   PubMed Web of Science ®Google Scholar
• El-Khairy L, Ueland PM, Nygard O, Refsum H, Vollset SE. 1999. Lifestyle and cardiovascular disease risk factors as determinants of total cysteine in plasma: the Hordaland Homocysteine study. American Journal of Clinical Nutrition 70:1016–1024.
   PubMed Web of Science ®Google Scholar
• Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 2000. Diabetes Care 23(Suppl. 1):4–19.
   Google Scholar
• Fenkci V, Fenkci S, Yılmazer M, Serteser M. 2003. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertility and Sterility 80:123–127.
   PubMed Web of Science ®Google Scholar
• Festa A, D'Agostino R, Howard G, Mykkanen L, Tracy R, Haffner S. 2000. Chronic subclinical inflammation as part of insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 102:42–47.
   PubMed Web of Science ®Google Scholar
• Godon T, Kannel WB. 1982. Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. American Heart Journal 103:1031–1039.
   PubMedGoogle Scholar
• Goodarzi MO, Azziz R. 2006. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Practice and Research: Clinical Endocrinology and Metabolism 20:193–205.
   PubMed Web of Science ®Google Scholar
• Guzelmeric K, Alkan N, Pirimoglu M, Unal O, Turan C. 2007. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecological Endocrinology 23:505–510.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. 1999. Homocysteine and vascular disease. Lancet 354:407–413.
   PubMed Web of Science ®Google Scholar
• Homocysteine Studies Collaboration. 2002. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. Journal of the American Medical Association 288:2023–2031.
   Google Scholar
• Janssen I, Katzmarzyk PT, Ross R. 2002. Body mass index, waist circumference, and health risk: Evidence in support of current National Institutes of Health guidelines. Archives of Internal Medicine 162:2074–2079.
   PubMedGoogle Scholar
• Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. 2001. Low grade chronic inflammation in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 86:2453–2455.
   PubMed Web of Science ®Google Scholar
• Legro RS, Finegood D, Dunaif A. 1998. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 83:2694–2698.
   PubMed Web of Science ®Google Scholar
• Legro RS, Kunselman AR, Dunaif A. 2001. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. American Journal of Medicine 111:607–613.
   PubMed Web of Science ®Google Scholar
• Lentz SR. 1997. Homocysteine and vascular dysfunction. Life Sciences 61:1205–1215.
   PubMed Web of Science ®Google Scholar
• McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, et al 1996. Recent trends in acute coronary heart disease: mortality, morbidity, medical care, and risk factors. New England Journal of Medicine 334:884–890.
   PubMed Web of Science ®Google Scholar
• Moran L, Teede H. 2009. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Human Reproduction Uptake 15:477–488.
   PubMed Web of Science ®Google Scholar
• Nasjek M, Kos-Kudla B, Ostrowska Z, Marek B, Kudla M, Siemi'nka L, et al 2007. Acute phase proteins: C-reactive protein and fibrinogen in young women with polycystic ovary syndrome. Pathophysiology 14:23–28.
   PubMedGoogle Scholar
• Puerpoint T, McKeigue P, Isaacs A, Wild S, Jacobs H. 1998. Mortality of women with polycystic ovary syndrome at long term follow-up. Journal of Clinical Epidemiology 51:581–586.
   PubMedGoogle Scholar
• Randeva HS, Lewandowski KC, Drzewoski J, Brooke-Wavell K, O'Callaghan C, Czupryniak L, et al 2002. Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 87:4496–4501.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Berneis K, Spinas G, Rini GB, Carmina E. 2009. Long-term consequences of polycystic ovary syndrome on cardiovascular risk. Fertility and Sterility 91:1563–1567.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Human Reproduction 19:41–47.
   PubMed Web of Science ®Google Scholar
• Salehi M, Bravo-Vera R, Sheikh A, Gouller A, Poretsky L. 2004. Pathogenesis of polycystic ovary syndrome: what is the role of obesity? Metabolism 53:358–376.
   PubMed Web of Science ®Google Scholar
• Schachter M, Raziel A, Friedler S, Strassburger D, Bern O, Ron-El R. 2003. Insulin resistance in patients with polycystic ovary syndrome is associated with elevated plasma homocysteine. Human Reproduction 18:721–727.
   PubMed Web of Science ®Google Scholar
• Schnyder G, Roffi M, Pin R, Flammer Y, Lange H, Eberli FR, et al 2001. Decreased rat of coronary restenosis after lowering of plasma homocysteine levels. New England Journal of Medicine 345:1593–1600.
   PubMed Web of Science ®Google Scholar
• Sharma ST, Nestler JE. 2006. Prevention of diabetes and cardiovascular disease in women with PCOS: Treatment with insulin sensitizers. Best Practice and Research Clinical Endocrinology 20:245–250.
   PubMed Web of Science ®Google Scholar
• Stamler JS, Slivka A. 1996. Biological chemistry of thiols in the vasculature and in vascular related disease. Nutrition Reviews 54:1–30.
   PubMed Web of Science ®Google Scholar
• Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al 1995. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology 15:821–826.
   PubMed Web of Science ®Google Scholar
• Tsilchorozidou T, Overton C, Conway GS. 2004. The pathophysiology of polycystic ovary syndrome. Clinical Endocrinology 60:1–17.
   PubMed Web of Science ®Google Scholar
• Turkey's Statistical Yearbook. 2005. [Türkiye İstatistik Yıllığı]. Turkey: State Institute of Statistics.
   Google Scholar
• Westerveld HE, Hoogendoorn M, de Jong AWF, Goverde AJ, Fauser BCJM, Dallinga-Thie GM, et al 2008. Cardiometabolic abnormalities in the polycystic ovary syndrome: Pharmacotherapeutic insights. Pharmacology Therapeutics 119:223–241.
   PubMed Web of Science ®Google Scholar
• Wild RA. 2002. Long-term health consequence of PCOS. Human Reproduction Uptake 8:231–241.
   PubMed Web of Science ®Google Scholar
• Yarali H, Yıldır A, Aybar F, Kabaci G, Bukulmez O, Tokgozoglu L, et al 2001. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Fertility and Sterility 76:511–516.
   PubMed Web of Science ®Google Scholar